Ajooni Biotech Limited — Others, 26-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Ajooni Biotech Limited reports no deviation in using Rs. 42.31 Cr raised from its Rights Issue. The funds have been allocated to land acquisition and site development (Rs. 7.79 Cr), plant and machinery (Rs. 1.46 Cr), working capital (Rs. 15.45 Cr), general corporate purposes (Rs. 5.09 Cr), and issue expenses (Rs. 0.46 Cr), with Rs. 15.30 Cr held as bank balance. This disciplined use of capital supports the company’s expansion and operational needs, reinforcing transparency and shareholder trust.